From manual to automated: building scalable workflows for autologous CAR-T cell manufacturing

Automation can enhance scalability, consistency, and efficiency in autologous CAR-T cell therapies, but adoption must be carefully phased and aligned with operational goals. This interactive poster illustrates how automation can overcome challenges in autologous CAR-T cell manufacturing, including patient variability, labor-intensive workflows, supply chain issues, and scalability, and includes soundbites from a panel of leading experts – Edwin Stone (CEO, Cellular Origins), Mojtaba Parvizi (Global Fast Trak Director, Cell Therapy, Cytiva), and Matthew Hewitt (Vice President,  CTO Manufacturing Division, Charles River Laboratories). NEW INTERACTIVE FORMAT Listen to our expert speaker. Watch the video. Read the summary. Focus in on the data. Download the PDF. It has never been easier to quickly access the information you want. All in one place – at the click of a button.

Please enter your email to access content Read now